Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06569082 · ClinicalTrials.gov registry record · NA
CD34+ Selected Stem Cell for Poor Graft Function or Graft Failure
A NA study of Graft Failure and Poor Graft Function, sponsored by NYU Langone Health.
- Recruiting
- Registry status
- NA
- Development phase
- 21
- Enrollment target
- 1
- Study location
NCT06569082 is a NA study of Graft Failure and Poor Graft Function that is actively recruiting participants, run by NYU Langone Health. The registered enrollment target is 21 participants, below the 68-participant average among 5 other Graft Failure trials with a reported enrollment target (69% lower). The trial reports 1 study location across 1 state.
The verdict
NCT06569082, a NA study of Graft Failure and Poor Graft Function, is actively recruiting participants, sponsored by NYU Langone Health.
- RECRUITING
- Registry status
- NA
- Development phase
- 21 participants
- Enrollment target
- 1
- Study location
Study Summary
The proposed trial is a single arm, non-randomized, single center pilot study utilizing CliniMACS CD34 Reagent System for patients following allogeneic hematopoietic stem cell transplant (HSCT) requiring treatment of graft dysfunction or failure.
Conditions Studied
Interventions
- DEVICE CD34+ Selected Donor Cell Boost
- PROCEDURE Blood Stem Cell Infusion
Study Locations (1)
New York
- NYU Langone Health - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 21 participants |
| Start Date | 2024-10-31 |
| Est. Completion | 2035-08 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06569082
The ClinicalTrials.gov registry entry for NCT06569082 describes a study currently listed as recruiting, categorized as NA. The registered enrollment target is 21 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 68-participant average among 5 other Graft Failure trials with a reported enrollment target (69% lower). The listed sponsor is NYU Langone Health, which has 1,164 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Graft Failure appearing as the primary indexed condition, and to 2 interventions - of which CD34+ Selected Donor Cell Boost is the first listed.
NCT06569082 reports 1 study location spanning 1 distinct geographic area - top geographies include New York.
Frequently Asked Questions
What is clinical trial NCT06569082 about?
NCT06569082 is a clinical study titled "CD34+ Selected Stem Cell for Poor Graft Function or Graft Failure". The proposed trial is a single arm, non-randomized, single center pilot study utilizing CliniMACS CD34 Reagent System for patients following allogeneic hematopoietic stem cell transplant (HSCT) requiring treatment of graft dysfunction or failure.
What is the current status of trial NCT06569082?
This trial is currently recruiting. It is a NA study. The enrollment target is 21 participants. The study started on 2024-10-31. Estimated completion is 2035-08.
What conditions does trial NCT06569082 study?
This clinical trial studies the following conditions: Graft Failure, Poor Graft Function.
What interventions are being tested in trial NCT06569082?
The interventions under investigation include: CD34+ Selected Donor Cell Boost (DEVICE), Blood Stem Cell Infusion (PROCEDURE).
Who is sponsoring clinical trial NCT06569082?
This trial is sponsored by NYU Langone Health, which has 1,164 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06569082 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Graft Failure
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Allo HSCT for High Risk Hemoglobinopathies
RECRUITING · Phase 2
-
Dd-cfDNA and Treg in Prediction of Kidney Transplant Acute Rejection
RECRUITING
-
Prevention of Graft Rejection in Hematopoietic Stem Cell Transplant (HSCT) Recipients
RECRUITING · Early Phase 1
-
Tumescence in HNC Skin Graft Reconstruction
ACTIVE NOT RECRUITING · Phase 3
-
Phase II Study Evaluating the Efficacy of Tacrolimus Extended Release Tablets to Twice Daily Tacrolimus Dosing Regimen
COMPLETED · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.